Search Results - "Wegge, Philip"

A randomized mCRPC phase 2b study of the BET bromodomain inhibitor (BETi) zen-3694 and enzalutamide vesus enzalutamide by Aggarwal, Rahul Raj, Schweizer, Michael Thomas, Nanus, David M., Attwell, Sarah, Campeau, Eric, Johnson, Emily, Wegge, Philip, Bauman, Lisa, Silverman, Michael H., Xu, Vandy, Zhu, Helena, Snyder, Margo, Lakhotia, Sanjay, Alumkal, Joshi J.

“…Abstract only TPS201 Background: Androgen receptor signaling inhibitors (ARSI), such as enzalutamide (Enza), and abiraterone (Abi), are standard therapies for…”
Get full text

Abstract CT095: A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) by Aggarwal, Rahul, Abida, Wassim, Schweizer, Michael, Pantuck, Allan, Nanus, David, Heath, Elisabeth, Lakhotia, Sanjay, Hansen, Henrik, Silverman, Michael, Bauman, Lisa, Snyder, Margo, Campeau, Eric, Norek, Karen, Attwell, Sarah, O'Farrell, Marie, Smith, Steve, Wegge, Philip, Jahagirdar, Ravi, Alumkal, Joshi

“…Background: Abiraterone (ABI) and enzalutamide (ENZ) have significant activity in mCRPC yet demonstrate frequent cross-resistance limiting efficacy of…”
Get full text